Navigation Links
Novelos Therapeutics Provides Product Pipeline Update
Date:5/16/2013

tive uptake of I-131-CLR1404 in a variety of tumor types where it persists in excess of 21 days."

In parallel with the ongoing Phase 1b fourth cohort, Novelos will be evaluating a range of potential HOT Phase 2 indications and trial designs including incorporation of multiple dosing, as well as combination of HOT with external beam radiotherapy or with radiosensitizing therapeutics.

GLOW2 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for both intraoperative tumor margin illumination and non-invasive tumor imaging.  Novelos plans to file an Investigational New Drug Application (IND) for GLOW2 by the end of 2013 and, subject to additional funding, expects to generate proof-of-concept data in cancer patients by the end of 2014.  GLOW2 may address the significant unmet medical need for better definition of tumor margins and nodal involvement, potentially reducing repeat surgeries and improving patient outcomes.

"A good example of the potential utility of CLR1502 (GLOW2) is in breast cancer surgery, where 25% of patients undergoing lumpectomy require repeat resection due to incomplete removal of the primary tumor and malignant lymph nodes," said Lee Wilke , M.D., Associate Professor (CHS), Division of General Surgery, and Director Breast Center at the University of Wisconsin Carbone Cancer Center. "An imaging agent that enables improved surgical accuracy by better defining malignant tissues could significantly improve patient outcomes and rapidly impact medical practice."

Mr. Palmin further noted, "Based on positive initial LIGHT imaging results in primary and metastatic brain cancer, we believe LIGHT has potential to address a significant unmet medical need for post-treatment efficacy assessment and differentiating tumor growth from pseudoprogression in brain cancer, potentially avoiding unnecessary surgeries, biopsies and other treatments.  While LIGHT human imaging data
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Prices $5.5 Million Public Offering
2. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
3. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
4. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
5. Novelos Therapeutics Closes $2 Million Private Placement
6. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Novelos Therapeutics Prices $5.4 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Mr. Xiaodong Wu, Chairman and Chief Executive Officer of ... of the Company,s American Depositary Shares ("ADSs") in the ...
... June 13, 2011 Tengion, Inc. (Nasdaq: ... trial of the Company,s lead clinical product candidate, the ... a urinary diversion following bladder removal (cystectomy). Tengion is ... approach as part of its ongoing clinical trial of ...
Cached Medicine Technology:China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 3Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 4
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... not always connected, researchers say , , FRIDAY, May 2 ... disturbances experienced by Alzheimer,s disease patients and the sleep ... team from the University of Washington, in Seattle, found ... aren,t always connected. , The researchers studied 44 older ...
... Epidemiology Center have found that approximately one in ten ... medications during a given week. These findings will ... & Asian Society for Pediatric Research Joint Meeting in ... widely marketed in the U.S. but surprisingly little is ...
... following is,being issued today by SEIU -- Inter-Con ... unfair labor practice strike against,Inter-Con to defend their ... the,first-ever group of hospital security officers to strike. ... were trying to form a,union for better conditions., ...
... Australian researchers have unveiled a new immunotherapy technique ... to AIDS. Details of the simple, cost-effective ... journal PLoS Pathogens. , There is an overwhelming ... therapies are expensive, impractical, and often highly toxic. ...
... WARSAW, Ind., May 2 Zimmer Holdings, Inc.,(NYSE ZMH; ... the,Deutsche Bank Securities 33rd Annual Health Care Conference, in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... says , , FRIDAY, May 2 (HealthDay News) -- Heart failure ... cancer, a new study finds. , Indeed, people in the ... inability to supply the body with oxygen-carrying blood, had measures ... that are seen in people with advanced cancer, Dr. David ...
Cached Medicine News:Health News:Sleep Troubles Vary Between Alzheimer's Patients, Caregivers 2Health News:1 in 10 children using cough, cold medications 2Health News:First-Ever Group of Hospital Security Officers to Strike over Unfair Labor Practices, Walk out of Facilities Across California on May 6 2Health News:Suffering of Heart Failure Similar to Cancer 2Health News:Suffering of Heart Failure Similar to Cancer 3
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
... & Solutions offers a wide variety ... needs of healthcare professionals. Whether you ... prefer a dry scrub brush in ... brushes provide the flexibility and options ...
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
Medicine Products: